# Regulation of cellular states via targeted phosphorylation of p53 using a nanobody-coupled kinase system

**Authors:** Hoe Eun Lim, Hae Yong Yoo

PMC · DOI: 10.1038/s41420-025-02821-1 · Cell Death Discovery · 2025-11-10

## TL;DR

Researchers created a system to phosphorylate p53 using a nanobody-coupled kinase, which altered cellular states and inhibited tumor growth in mice.

## Contribution

A novel nanobody-coupled kinase system was developed to phosphorylate p53 and regulate cellular states without external stimuli.

## Key findings

- The system effectively phosphorylated p53, stabilizing its protein levels and inducing p21 expression.
- Phosphorylation delayed cell cycle progression and suppressed cell growth in cancer cells.
- Combining the system with chemotherapy drugs enhanced cytotoxicity and inhibited tumor growth in a mouse model.

## Abstract

Phosphorylation participates in numerous signal transduction processes, including proliferation, differentiation, apoptosis, and cellular response to stimuli. Understanding its regulatory mechanisms is essential for advancing therapeutic interventions. In this study, we developed a target protein phosphorylation (TPP) system, consisting of a nanobody fused to a kinase domain, to investigate its ability to phosphorylate target proteins and regulate their cellular characteristics. We first verified that the nanobody-coupled kinase effectively phosphorylates GFP. Subsequently, we focused on p53 phosphorylation, identifying specific phosphorylation sites targeted by the system. This phosphorylation resulted in stabilization of p53 protein levels, inducing p21 expression, delaying cell cycle progression and suppressing cell growth. Furthermore, combining the TPP system with chemotherapeutic drugs (5-Fluorouracil and Oxaliplatin) enhanced cytotoxicity in colorectal cancer cells. The TPP system achieved p53 phosphorylation without external stimuli, inducing a DNA-damaged state in cells. In vivo, doxycycline-induced expression of the TPP system in a xenograft mouse model significantly inhibited tumor growth. This work demonstrates the ability to phosphorylate key regulatory proteins and alter cellular states, suggesting applications in studying phosphorylation-related pathways and developing therapies for diseases associated with dysregulated phosphorylation.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026]
- **Chemicals:** 5-Fluorouracil (PubChem CID 3385), Oxaliplatin (PubChem CID 9887053), doxycycline (PubChem CID 54671203)
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}
- **Diseases:** colorectal cancer (MESH:D015179), tumor (MESH:D009369), cytotoxicity (MESH:D064420)
- **Chemicals:** 5-Fluorouracil (MESH:D005472), Oxaliplatin (MESH:D000077150), doxycycline (MESH:D004318)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12603232/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12603232/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12603232/full.md

---
Source: https://tomesphere.com/paper/PMC12603232